Athira Pharma Inc (NYSE: ATHA) — Perfil da empresa, notícias e dados financeiros
Athira Pharma focuses on developing therapies for neurodegenerative diseases like Alzheimer's with innovative treatments.
Athira Pharma Inc
Athira Pharma (NASDAQ:ATHA) is a forward-thinking biotechnology company focused on developing therapies for neurodegenerative diseases. The company, listed on the NASDAQ, channels its efforts into innovative treatments aimed at slowing and potentially reversing the effects of conditions like Alzheimer's and Parkinson's disease. Athira is actively working on its leading project, fosgonimeton, a treatment that targets synaptic health and neuron connectivity, critical factors in cognitive function. By prioritizing research and development, Athira aims to address unmet medical needs and improve patients’ lives through breakthrough therapies. Their ultimate objective is to create groundbreaking solutions that tackle the underlying causes of neurodegeneration.
Resumo
Operações
Produtos e/ou serviços de Athira Pharma Inc
- Leading project focuses on ATH-1017, a small molecule therapeutic aimed at enhancing neuronal health by targeting HGF/MET receptor systems, particularly for Alzheimer's disease treatment.
- The company is advancing the development of its second-generation Renova platform for creating neuroprotective and regenerative small molecules.
- Research includes efforts to expand the therapeutic potential of the HGF/MET pathway for neurology and other domains.
- Aiming to address a wide array of neurodegenerative diseases, the company invests in discovering innovative therapies leveraging proprietary technology.
- Collaborative partnerships are pursued for clinical development, expanding access to novel treatment avenues for patients worldwide.
- Investor and shareholder engagement activities are prioritized to support ongoing research and clinical trials.
equipe executiva do Athira Pharma Inc
- Dr. Mark J. Litton M.B.A., Ph.D.President, CEO & Director
- Dr. Kevin Church Ph.D.Chief Scientific Officer
- Mr. Mark F. Worthington J.D.General Counsel, Chief Compliance Officer & Corporate Secretary
- Mr. Robert RenningerChief Financial Officer
- Ms. Julie RathbunHead of Investor Relations
- Dr. Javier San Martin M.D.Chief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Athira Pharma Inc.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -102,3 mi | -105,6 mi | |
| 0 | -100,9 mi | -96,9 mi | |
| 0 | -125,5 mi | -117,7 mi | |
| 0 | -104 mi | -95,6 mi |